Edition:
United States

Health

Topics also related to Technology:

U.S. reform a future boost for drugmakers, others

NEW YORK Could U.S. healthcare reform improve the industry's profit prognosis?

Photo

Hassan sees Merck retaining Remicade

NEW YORK Fred Hassan, former head of Schering-Plough Corp, said Merck & Co is likely to prevail over Johnson & Johnson in its battle to retain overseas rights to the blockbuster arthritis drug Remicade.

Photo

FDA chief defends H1N1 vaccine supply

NEW YORK The head of the U.S. Food and Drug Administration defended the agency's decision not to use an additive that could have stretched swine flu vaccine supplies, adding that doses should be coming more regularly. | Video

Drugmakers hopeful of better FDA climate

NEW YORK Drugmakers who have complained for years about caution and unpredictability at the U.S. Food and Drug Administration see signs the climate for reviewing new medicines may be improving.

Glaxo sees recurring pandemic flu business

NEW YORK Sales of flu treatments due to the H1N1 swine flu pandemic may be sustainable beyond the current winter season, as governments around the world overhaul their long-term strategy on stockpiles.

Photo

FDA head to speed reviews, visit China

NEW YORK The U.S. Food and Drug Administration is working to increase the speed of drug reviews and clean up problems in the division that oversees medical devices, the agency's commissioner said on Thursday.

Glaxo CEO sees little risk to margins

NEW YORK GlaxoSmithKline Plc does not expect profit margins to slip substantially, despite an aggressive drive to diversify into areas like emerging markets and consumer health, its chief executive said on Thursday.

Photo

FDA seeks to streamline device unit

NEW YORK The new head of the U.S. Food and Drug Administration said she is working to clean up the agency's troubled device unit, including a review of how it approves medical devices.

Glaxo sees Benlysta as "very major" opportunity

NEW YORK GlaxoSmithKline Plc said on Thursday it expects its experimental lupus drug Benlysta to be a "very major" product and contribute meaningfully to the company's bottom line.

Photo

Medical device prices in crosshairs of reform

NEW YORK Cash-strapped hospitals are stepping up pressure on the prices of medical devices -- from knee replacements to diagnostic tests and surgical systems -- as momentum builds toward U.S. healthcare reform.

Photo

Pfizer says absorbing Wyeth at top speed

NEW YORK Pfizer Inc Chief Executive Officer Jeffrey Kindler said the drugmaker is integrating its Wyeth purchase far faster than previous big acquisitions, and it will no longer be overly dependent on one or two blockbuster medications.

Speakers

Topics also related to Technology: